At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 12 enrolled
Drug / intervention
Insulin Degludec +1 moredrug
Likely dose
Insulin Degludec 10 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of the Administration of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus Drug-naïve
In Brief
A Phase 4 clinical trial evaluating Insulin Degludec and Insulin Glargine for Type 2 Diabetes Mellitus. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Type 2 diabetes mellitus (T2DM) is characterized by wide fluctuations of glucose. The long-acting insulin has showed to improve glycemic variability however the behavior of insulin glargine versus insulin degludec is unknown.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesMexico
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
Primary CompletionJul 2015
First PostedFeb 2016
Study CompletionNov 2016
TodayJul 2026
First PostedFeb 11, 2016
Enrollment StartNov 1, 2013
Primary CompletionJul 1, 2015
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.4 years ago
Interventions
Insulin Degludecdrug
Insulin Degludec 10 IU SC every 24 hours for 6 days
Insulin Glarginedrug
Insulin Glargine 10 IU SC every 24 hours for 6 days